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a Tunneled Dialysis Catheter (TDC) Have Similar
Long Term Survival After Arteriovenous Fistula
(AVF) or Arteriovenous Graft (AVG) Placement
Theodore H. Yuo, Rabih Chaer, Ellen D. Dillavou, Luke
K. Marone, Michel S. Makaroun. Surgery, University of
PIttsburgh, Pittsburgh, Pa
Objectives: SVS guidelines suggest AVF is associated
with a survival advantage over AVG. However, AVF often
require months to become functional, increasing TDC use
in patients starting HD with TDC. We sought to compare
survival in ESRD patients based on HD access type.
Methods: Using US Renal Data System (USRDS)
databases, we identiﬁed incident HD patients in 2005 and
followed them through 2008. Initial access type was assessed
using USRDS data collection forms. Attempts at AVF and
AVG creation were identiﬁed by CPT codes. Patients were
divided into groups based on whether an attempt at AVF
or AVG was undertaken within 3 months after initiation of
HD. Log-rank tests were used for pairwise survival compar-
isons, stratiﬁed by age. The primary outcome was vital status.
Results: We analyzed 46,672 patients who started HD
in 2005 and survived at least 3 months. TDC was the initial
access for 80% of patients; 52% were 65 years or older. At 1
year, patients starting HD with AVF had improved survival
compared to patients who initiated HD through TDC (88%
vs 76%; P < .001) or through AVG (88% vs 83%; P < .001).
In patients over 65 who initiate HD with TDC, creation of
AVF and AVG are associated with identical survival (P ¼
NS), with both signiﬁcantly better than continued HD
through TDC (P < .001) (Fig).
Conclusions: Initiation of HD through AVF is associ-
ated with improved survival compared to AVG and TDC,
but is a small fraction of ESRD patients. In patients over
65 that initiate HD through TDC, creation of AVF is
not superior to AVG in terms of survival.
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T. H. Yuo: Nothing to disclose.Fig.A Comparison of Patency Between One and Two Stage
Arteriovenous Fistula Transpositions
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Objectives: Renewed interest in arteriovenous ﬁstula
(AVF) transposition has arisen as emphasis is being placed on
autologous hemodialysis access construction. We report our
experience with one and two stage techniques for AVF
transposition.
Methods: A database of all patients who had AVF
placed between January 2008 and June 2011 was retro-
spectively reviewed. Patients were stratiﬁed into those
whose AVF was transposed using a one stage technique
(AVFT-1) and those done with a two stage technique
(AVFT-2). Outcomes measured were assisted primary
and secondary patency. Marginal survival models utilizing
Cox proportional hazards regression were used for statis-
tical comparison. Results are reported as hazard ratio
(HR) and 95% conﬁdence intervals (CI).
Results: A total of 125 AVF were created using a trans-
position technique. AVFT-1 (n¼ 38) and AVFT-2 (n¼ 87)
were analyzed. After accounting for multivariate association
with age, diabetes, PAD, tobacco use, previous number of
accesses, and presence of tunneled catheter at AVF creation,
AVFT-2 was associated with both better assisted primary
(HR, 0.47; CI, 0.25-0.90) and secondary patency (HR,
0.44; CI, 0.23-0.87) when compared to AVFT-1.
Conclusions: In our experience two stage operations
demonstrated improved assisted primary and secondary
patency and as a corollary could extend the duration of
autologous access in challenging hemodialysis patients.
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Nothing to disclose; W. John: Nothing to disclose;Fig. Kaplan-Meier survival curves of secondary patency for one-
stage and two-stage AVF transposition.
